By admin 
The Federal Trade Commission (FTC) has finalized a historic settlement with CVS Caremark, one of the nation’s largest pharmacy benefit managers (PBMs), resolving a high-stakes legal battle over allegations that the company manipulated the pharmaceutical market to artificially inflate the cost of insulin. This agreement, announced on July 14, 2026, marks a pivotal moment in the federal government’s multi-year crackdown on the "Big Three" PBMs—CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s Optum Rx—which together control nearly 80% of the prescription drug market in the United States. The settlement aims to dismantle a "perverse" system of financial incentives that the FTC argues has prioritized corporate profits over the health and financial stability of millions of Americans living with diabetes.
According to the terms of the settlement, CVS Caremark, a subsidiary of CVS Health, must implement sweeping structural changes to its business practices, particularly regarding how it negotiates with drug manufacturers and how it passes savings to health plans and patients. The FTC estimates that the deal will save American consumers and employers up to $8.5 billion in out-of-pocket costs over the next decade. Furthermore, the agency project that an additional $4.5 billion in savings will be unlocked through the mandatory implementation of pharmacy counter rebates, ensuring that discounts negotiated behind closed doors are finally reflected in the prices patients pay at the point of sale.
The FTC’s original complaint, filed in late 2024, painted a damning picture of the PBM industry’s role in the insulin crisis. For decades, the list price of insulin—a hormone discovered over a century ago—skyrocketed, despite the underlying technology remaining relatively stable. The FTC alleged that CVS Caremark and its competitors facilitated this trend by demanding massive rebates from pharmaceutical manufacturers in exchange for "preferred" status on their formularies (the lists of drugs covered by insurance). Because PBMs often retain a percentage of these rebates or base their administrative fees on a drug’s list price, they were incentivized to favor high-priced insulin products over more affordable generics or biosimilars. This created a "rebate trap" where manufacturers were forced to hike list prices to afford the deep rebates demanded by PBMs, while patients with high-deductible plans or coinsurance were forced to pay the inflated list price out of pocket.
In the words of the FTC, this system allowed PBMs to "line their pockets" at the expense of vulnerable patients. The agency argued that CVS Caremark used its immense market power to exclude lower-cost insulin products from its formularies, effectively blocking competition and forcing patients to use more expensive brand-name versions. For a patient with Type 1 diabetes, for whom insulin is a physiological necessity rather than a choice, these pricing maneuvers often meant the difference between being able to afford rent and being able to afford the medication required to stay alive.
The settlement specifically targets the lack of transparency that has long shielded PBM operations from public and regulatory scrutiny. Under the new agreement, CVS Caremark is required to provide "clear and actionable" data to its clients, including employers and health plans, regarding the total value of rebates collected and how those funds are being utilized. This move is designed to empower plan sponsors to hold PBMs accountable and ensure that the savings meant for beneficiaries are not being diverted into corporate coffers. Additionally, the mandate for pharmacy counter rebates is expected to have an immediate impact on the "sticker shock" patients experience at the pharmacy. By applying a portion of the manufacturer rebate directly to the patient’s cost-sharing at the register, the settlement effectively bypasses the traditional PBM profit-retention model.
The legal and economic implications of this settlement extend far beyond CVS Caremark. By securing these concessions, the FTC has established a new regulatory floor for the entire PBM industry. The "Big Three" have long operated as vertically integrated behemoths; CVS Health, for instance, owns a massive retail pharmacy chain, a major health insurer (Aetna), and the Caremark PBM. Critics have argued that this integration creates inherent conflicts of interest, where the PBM is incentivized to steer patients toward pharmacies and insurance plans owned by the parent company, often at the expense of independent pharmacies and patient choice. While the settlement does not mandate a full "breakup" of CVS Health, the required changes to its rebate and formulary practices represent a significant curtailment of its market influence.
The backdrop of this settlement is a decades-long outcry over the "insulin cliff." Between 1996 and 2016, the list price of some insulin products increased by over 1,000%. While manufacturers like Eli Lilly, Novo Nordisk, and Sanofi have faced intense criticism, the FTC’s investigation shifted the spotlight toward the intermediaries who control the flow of money. The agency’s data suggests that as list prices rose, the "net price"—the amount the manufacturer actually receives after paying rebates—often remained flat or even declined. The difference was captured by PBMs and other supply chain entities, leaving the patient to pay a price based on the high list figure rather than the lower net figure.
Industry analysts suggest that this settlement may lead to a domino effect. The FTC’s litigation against Cigna’s Express Scripts and UnitedHealth’s Optum Rx is still pending, but legal experts believe the CVS deal provides a blueprint for future resolutions. If the other major PBMs are forced to adopt similar transparency and rebate-sharing measures, the total savings for the U.S. healthcare system could reach tens of billions of dollars. This would mark a significant victory for the Biden-Harris administration’s—and subsequent administrations’—ongoing efforts to tackle high drug costs through both legislative measures, like the Inflation Reduction Act, and aggressive antitrust enforcement.
However, the settlement is not without its critics. Some consumer advocacy groups argue that $8.5 billion over 10 years, while significant, is a fraction of the profits PBMs have extracted from the healthcare system over the past decade. There are also concerns that PBMs may find new ways to recoup lost revenue, such as by introducing new "administrative fees" or "data fees" that are not explicitly covered by the settlement’s prohibitions. "This is a major step forward, but we must remain vigilant," said one healthcare economist. "The PBM model is incredibly complex and opaque. Whenever you close one loophole, these companies have a history of finding another."
For patients, the news is a glimmer of hope after years of advocacy. Groups like T1International and Insulin for All have spent years highlighting the dangers of insulin rationing, a practice where patients take less than their prescribed dose to make their supply last longer. Rationing can lead to diabetic ketoacidosis (DKA), permanent organ damage, and death. By forcing a reduction in out-of-pocket costs and increasing the availability of lower-cost biosimilars on formularies, the FTC hopes to make insulin rationing a relic of the past.
The settlement also requires CVS Caremark to cease certain "exclusionary" practices that prevented lower-cost insulin biosimilars from gaining market share. In the past, PBMs would often refuse to cover a biosimilar unless its manufacturer offered a rebate that exceeded the rebate of the brand-name drug. This often made it impossible for new, lower-priced entrants to compete, as they could not afford the massive "entry fees" required by the PBMs. The new rules mandate that formulary placement must be based on the lowest cost to the plan and the patient, rather than the highest rebate to the PBM.
As the healthcare industry processes the details of this agreement, the focus will now turn to implementation. The FTC has stated it will appoint an independent monitor to oversee CVS Caremark’s compliance with the settlement terms for the next decade. This monitor will have the authority to review contracts, audit financial records, and ensure that the promised $8.5 billion in savings actually reaches the intended recipients. For CVS Health, the settlement represents a costly but necessary step to move past the regulatory clouds that have hung over its PBM business. In statements following the announcement, the company emphasized its commitment to affordability and suggested that the changes would lead to a more "sustainable" pharmaceutical marketplace.
Ultimately, the CVS Caremark settlement is a testament to the shifting tide of pharmaceutical regulation in the United States. It signals that the era of unchecked PBM dominance may be coming to an end, replaced by a framework that demands greater transparency, fairer competition, and a direct link between negotiated savings and patient costs. While the battle over drug pricing is far from over, this agreement provides a roadmap for how the federal government can use its antitrust authority to protect the most vulnerable members of the public from the complexities of a "perverse" financial system. The coming years will reveal whether these structural changes are enough to permanently lower the cost of insulin and other lifesaving medications, or if further, more radical interventions in the PBM industry will be required.
